Aromatherapy Inhaler Use for HSCT Distress
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.
Eligibility criteria
Qualifiers
Autologous and Allogeneic patients admitted to E1 for planned HSCT
Patients with hematologic malignancies requiring HSCT
No allergies to lavender or peppermint essential oils
Must have received chemotherapy during preparative regimen (single or multi-agent regimen)
Disqualifiers
Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion
Patients receiving a transplant for a germ cell tumor diagnosis
Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)
Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4
Trial design
Treatments tested in this trial
- Aromatherapy Stick
- Standard of Care
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
1Stanford University94305, StanfordCalifornia, United States
Sponsors and collaborators
Stanford University
Lead sponsor
Source ClinicalTrials.gov